
David Dongliang Ge
Apostle Inc. , USA
Biography
David Dongliang Ge is the CEO and President of Apostle Inc., in Sunnyvale, CA, focusing on novel bioinformatics-enabled nanotechnologies for cancer early detection. Previously, he was the President of BioSciKin Co. and Simcere Diagnostics Co., China focusing on the licensing and sales of diagnostic technologies. Between 2011 and 2016, he was the Director of Bioinformatics at Gilead Sciences, where he founded and provided leadership to the bioinformatics group and provided the strategic input to related infrastructure and process. He and his group led the phylogenomic analytical support for the critical regulatory approval of Sovaldi, a world-leading anti-HCV drug. In 2014 and 2015, he was invited to be a Member of the US National Human Genome Research Institute Special Emphasis Panel. Prior to Gilead, he was appointed as Assistant Professor of Biostatistics and Bioinformatics and Assistant Professor in Medicine at Duke University School of Medicine. He has received his PhD in Biostatistics and Genetic Epidemiology from Peking Union Medical College and Chinese Academy of Medical Sciences in 2004. He has authored or co-authored over 70 peer-reviewed articles.
Abstract
Abstract : Genomic approaches in modern biotechnology-from discovery, translation to implementation